News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,023 Results
Type
Article (41366)
Company Profile (263)
Press Release (689378)
Multimedia
Podcasts (92)
Webinars (20)
Section
Business (204849)
Career Advice (2032)
Deals (35584)
Drug Delivery (129)
Drug Development (81523)
Employer Resources (173)
FDA (16512)
Job Trends (14983)
News (346840)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2596)
Accelerated approval (47)
Adcomms (26)
Allergies (171)
Alliances (49581)
ALS (211)
Alzheimer's disease (1801)
Antibody-drug conjugate (ADC) (447)
Approvals (16899)
Artificial intelligence (666)
Autoimmune disease (294)
Automation (56)
Bankruptcy (362)
Best Places to Work (11635)
BIOSECURE Act (20)
Biosimilars (222)
Biotechnology (170)
Bladder cancer (195)
Brain cancer (73)
Breast cancer (754)
Cancer (5832)
Cardiovascular disease (471)
Career advice (1724)
Career pathing (42)
CAR-T (331)
CDC (57)
Celiac Disease (3)
Cell therapy (899)
Cervical cancer (47)
Clinical research (70863)
Collaboration (2061)
Company closure (5)
Compensation (1404)
Complete response letters (80)
COVID-19 (2743)
CRISPR (108)
C-suite (1132)
Cystic fibrosis (152)
Data (7932)
Decentralized trials (3)
Denatured (27)
Depression (161)
Dermatology (87)
Diabetes (586)
Diagnostics (6930)
Digital health (55)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (319)
Drug pricing (201)
Drug shortages (31)
Duchenne muscular dystrophy (283)
Earnings (92115)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119556)
Executive appointments (1082)
FDA (20249)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (34)
Funding (1729)
Gene editing (234)
Generative AI (56)
Gene therapy (722)
GLP-1 (1055)
Government (4732)
Grass and pollen (6)
Guidances (408)
Healthcare (19006)
HIV (79)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (288)
Immuno-oncology (93)
Indications (194)
Infectious disease (3081)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (291)
Interviews (319)
IPO (16667)
IRA (50)
Job creations (3647)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (101)
Layoffs (563)
Leadership (39)
Legal (7953)
Liver cancer (100)
Longevity (32)
Lung cancer (767)
Lymphoma (429)
Machine learning (60)
Management (59)
Manufacturing (1051)
MASH (188)
Medical device (13936)
Medtech (14061)
Mergers & acquisitions (20170)
Metabolic disorders (1502)
mRNA (205)
Multiple sclerosis (188)
NASH (17)
Neurodegenerative disease (417)
Neuropsychiatric disorders (105)
Neuroscience (3311)
Neurotech (1)
NextGen: Class of 2026 (6520)
Non-profit (4530)
Now hiring (78)
Obesity (703)
Opinion (288)
Ovarian cancer (220)
Pain (256)
Pancreatic cancer (304)
Parkinson's disease (362)
Partnered (33)
Patents (597)
Patient recruitment (673)
Peanut (62)
People (59605)
Pharmaceutical (58)
Pharmacy benefit managers (32)
Phase 1 (22086)
Phase 2 (31222)
Phase 3 (23226)
Pipeline (8803)
Policy (319)
Postmarket research (2569)
Preclinical (9414)
Press Release (64)
Prostate cancer (304)
Psychedelics (54)
Radiopharmaceuticals (323)
Rare diseases (1078)
Real estate (5971)
Recruiting (70)
Regulatory (25416)
Reports (56)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (22)
RSV (88)
Schizophrenia (176)
Series A (289)
Series B (213)
Service/supplier (11)
Sickle cell disease (112)
Special edition (24)
Spinal muscular atrophy (166)
Sponsored (48)
Startups (3642)
State (2)
Stomach cancer (18)
Supply chain (127)
Tariffs (87)
The Weekly (63)
Vaccines (1092)
Venture capital (108)
Weight loss (451)
Women's health (128)
Worklife (20)
Date
Today (156)
Last 7 days (850)
Last 30 days (3654)
Last 365 days (30239)
2026 (12764)
2025 (30174)
2024 (35209)
2023 (40074)
2022 (51173)
2021 (55708)
2020 (54081)
2019 (46537)
2018 (35015)
2017 (32108)
2016 (31482)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (93)
Alaska (7)
Arizona (349)
Arkansas (14)
Asia (39682)
Australia (6510)
California (13314)
Canada (3776)
China (1342)
Colorado (567)
Connecticut (579)
Delaware (410)
Europe (85887)
Florida (1996)
Georgia (427)
Hawaii (3)
Idaho (62)
Illinois (1054)
India (90)
Indiana (601)
Iowa (23)
Japan (539)
Kansas (131)
Kentucky (50)
Louisiana (41)
Maine (76)
Maryland (1595)
Massachusetts (9494)
Michigan (364)
Minnesota (720)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (143)
New Hampshire (84)
New Jersey (3497)
New Mexico (29)
New York (3483)
North Carolina (1689)
North Dakota (9)
Northern California (6677)
Ohio (399)
Oklahoma (23)
Oregon (41)
Pennsylvania (2680)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (86)
South Dakota (2)
Southern California (5256)
Tennessee (213)
Texas (2123)
United States (46961)
Utah (397)
Vermont (1)
Virginia (322)
Washington D.C. (80)
Washington State (1062)
West Virginia (4)
Wisconsin (126)
Wyoming (2)
731,023 Results for "arvinas inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
·
24 min read
Press Releases
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
May 12, 2026
·
7 min read
Press Releases
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 5, 2026
·
1 min read
Press Releases
Arvinas to Participate in Upcoming March 2026 Investor Conferences
February 23, 2026
·
1 min read
Approvals
FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.
May 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 3, 2026
·
13 min read
Press Releases
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026
·
28 min read
Press Releases
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
February 17, 2026
·
1 min read
Press Releases
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
February 12, 2026
·
7 min read
Press Releases
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
May 4, 2026
·
4 min read
1 of 73,103
Next
